BlossomHill net loss widens 79.35% to $23.8 million in Q2 FY26; R&D expenses rise 70.78% to $21.4 million - BLSM News | RalliesBlossomHill net loss widens 79.35% to $23.8 million in Q2 FY26; R&D expenses rise 70.78% to $21.4 million
B
BLSM• Cash position and financing
- Cash and cash equivalents were $95.4 million at June 30.
- An August IPO raised $168.3 million in gross proceeds.
Pipeline and regulatory updates
- The FDA granted Fast Track designation for BH-30643.
- A Q4 end-of-Phase 1 meeting is planned.
- First patient dosing in a pivotal Phase 2 is expected in Q1 2027.
Q2 FY26 loss and expense growth
- BlossomHill posted a Q2 2026 net loss of $23.8 million, widening from $13.2 million a year earlier.
- R&D expense climbed 70.8% to $21.4 million, while G&A more than doubled to $3.3 million.
- R&D rose primarily on higher SOLARA trial costs, BH-501284 IND-enabling work, and higher personnel, facilities and overhead.
